Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS)

Victoria Chernyak, Kathryn J. Fowler, Jay P. Heiken, Claude B. Sirlin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Use of gadoxetate disodium, a hepatobiliary gadolinium-based agent, in patients with chronic parenchymal liver disease offers the advantage of improved sensitivity for detecting hepatocellular carcinoma (HCC). Imaging features of liver observations on gadoxetate-enhanced MRI may also serve as biomarkers of recurrence-free and overall survival following definitive treatment of HCC. A number of technical and interpretative pitfalls specific to gadoxetate exist, however, and needs to be recognized when protocoling and interpreting MRI exams with this agent. This article reviews the advantages and pitfalls of gadoxetate use in patients at risk for HCC, and the potential impact on Liver Imaging Reporting and Data System (LI-RADS) imaging feature assessment and categorization. Level of Evidence: 5. Technical Efficacy Stage: 2. J. Magn. Reson. Imaging 2019.

Original languageEnglish (US)
JournalJournal of Magnetic Resonance Imaging
DOIs
StateAccepted/In press - Jan 1 2019
Externally publishedYes

Fingerprint

Information Systems
Liver Diseases
Hepatocellular Carcinoma
Chronic Disease
Liver
Gadolinium
Proxy
Biomarkers
Recurrence
Survival
gadolinium ethoxybenzyl DTPA
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{0934577678054e4d8c5b204e916600b3,
title = "Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS)",
abstract = "Use of gadoxetate disodium, a hepatobiliary gadolinium-based agent, in patients with chronic parenchymal liver disease offers the advantage of improved sensitivity for detecting hepatocellular carcinoma (HCC). Imaging features of liver observations on gadoxetate-enhanced MRI may also serve as biomarkers of recurrence-free and overall survival following definitive treatment of HCC. A number of technical and interpretative pitfalls specific to gadoxetate exist, however, and needs to be recognized when protocoling and interpreting MRI exams with this agent. This article reviews the advantages and pitfalls of gadoxetate use in patients at risk for HCC, and the potential impact on Liver Imaging Reporting and Data System (LI-RADS) imaging feature assessment and categorization. Level of Evidence: 5. Technical Efficacy Stage: 2. J. Magn. Reson. Imaging 2019.",
author = "Victoria Chernyak and Fowler, {Kathryn J.} and Heiken, {Jay P.} and Sirlin, {Claude B.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jmri.26540",
language = "English (US)",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS)

AU - Chernyak, Victoria

AU - Fowler, Kathryn J.

AU - Heiken, Jay P.

AU - Sirlin, Claude B.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Use of gadoxetate disodium, a hepatobiliary gadolinium-based agent, in patients with chronic parenchymal liver disease offers the advantage of improved sensitivity for detecting hepatocellular carcinoma (HCC). Imaging features of liver observations on gadoxetate-enhanced MRI may also serve as biomarkers of recurrence-free and overall survival following definitive treatment of HCC. A number of technical and interpretative pitfalls specific to gadoxetate exist, however, and needs to be recognized when protocoling and interpreting MRI exams with this agent. This article reviews the advantages and pitfalls of gadoxetate use in patients at risk for HCC, and the potential impact on Liver Imaging Reporting and Data System (LI-RADS) imaging feature assessment and categorization. Level of Evidence: 5. Technical Efficacy Stage: 2. J. Magn. Reson. Imaging 2019.

AB - Use of gadoxetate disodium, a hepatobiliary gadolinium-based agent, in patients with chronic parenchymal liver disease offers the advantage of improved sensitivity for detecting hepatocellular carcinoma (HCC). Imaging features of liver observations on gadoxetate-enhanced MRI may also serve as biomarkers of recurrence-free and overall survival following definitive treatment of HCC. A number of technical and interpretative pitfalls specific to gadoxetate exist, however, and needs to be recognized when protocoling and interpreting MRI exams with this agent. This article reviews the advantages and pitfalls of gadoxetate use in patients at risk for HCC, and the potential impact on Liver Imaging Reporting and Data System (LI-RADS) imaging feature assessment and categorization. Level of Evidence: 5. Technical Efficacy Stage: 2. J. Magn. Reson. Imaging 2019.

UR - http://www.scopus.com/inward/record.url?scp=85059508801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059508801&partnerID=8YFLogxK

U2 - 10.1002/jmri.26540

DO - 10.1002/jmri.26540

M3 - Article

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

ER -